Compare Regeneron Pharmaceuticals Inc (REGN) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs T Rowe Price Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.33 (market cap $76.14B), while T Rowe Price Group Inc trades at $105.18 (market cap $22.23B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.4× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and T Rowe Price Group Inc for 115 Days on average.
| REGN | TROW | |
|---|---|---|
Market Cap | $76.14B | $22.23B |
Volume | 500,239 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $852.03 | $121.68 |
52-Week Low | $557.73 | $86.19 |
Typical Hold Time | 107 Days | 115 Days |
Enterprise Value | $70.85B | $19.43B |
Dividend Yield | 0.51% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
T. Rowe Price Group (TROW) trades at $104.07, showing modest daily gains of 0.45%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a low P/E of 10.46 and robust profitability metrics. Recent earnings show two consecutive beats, with Q3 2026 results pending. The company maintains solid cash flow generation and recently announced a $1.30 dividend payment for September 2026, continuing its 40-year dividend growth streak.
TROW offers value characteristics with attractive valuation multiples and consistent dividend growth, though technical weakness and mixed analyst sentiment suggest near-term caution. Upside potential exists to the $112 consensus target, but investors face risks from market-sensitive revenue streams and ongoing net outflows despite AUM growth to $1.90 trillion as of August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
